Print this page

Aptiva® Antiphospholipid Syndrome Reagents Receive CE Mark

We are pleased to announce that we have recently obtained the CE (Conformité Européenne) mark for the Aptiva® Antiphospholipid Syndrome (APS) Immunoglobulin G (IgG) and Immunoglobulin M (IgM) reagents.

This significant achievement was made possible under the European Union’s (EU) In Vitro Diagnostic Regulation (IVDR). These new APS reagents complement the existing Aptiva Celiac Disease and Connective Tissue Diseases (CTD) Essential reagents, effectively expanding the range of CE marked analytes detectable by Aptiva to 19.

Aptiva utilizes particle-based multi-analyte technology (PMAT), enabling the simultaneous processing of multiple analytes from a single patient sample aliquot. Leveraging PMAT, the Aptiva APS reagent can deliver up to 120 results per hour, significantly reducing hands-on time for laboratory personnel.

In addition to APS, CTD, and Celiac Disease assays, Aptiva is poised to target additional autoimmune disease states, with over 60 analytes currently in various stages of advanced development.

These analytes hold promise for enhancing the accuracy of autoimmune disease diagnosis and facilitating improved patient management. Congratulations to the entire Autoimmunity team for their invaluable contributions to reaching this significant milestone.

Last modified on Friday, 08 March 2024 10:20